Source: International Congress 2018 – Primary care management of respiratory conditions
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. Watz (Grosshansdorf, Germany), H. Magnussen (Grosshansdorf, Germany), R. Rodriguez-Roisin (Barcelona, Spain), K. Tetzlaff (Ingelheim am Rhein, Germany), M. Haensel (Ingelheim am Rhein, Germany), A. Mueller (Biberach an der Riss, Germany), C. Vogelmeier (Marburg, Germany). ICS withdrawal and exacerbation risk by GOLD 2017 Report: post hoc analysis of the WISDOM trial. 289

Member's Comments

No comment yet.

Related content which might interest you: Impact of grouping patients by 2017 GOLD strategy assessment criteria: a post hoc analysis of the TONADO and OTEMTO trials Source: International Congress 2017 – COPD management: new findings from large studies Year: 2017 Treatment response in COPD: does FEV1 say it all? A post hoc analysis of the CRYSTAL study Source: ERJ Open Res, 5 (1) 00243-2018; 10.1183/23120541.00243-2018 Year: 2019 The impact of grouping patients by the 2017 GOLD COPD strategy on response to therapy: post hoc results from the TONADO tiotropium+olodaterol trials Source: International Congress 2017 – What is new in COPD diagnosis and classification? Year: 2017 Characterising patients with COPD by baseline short-acting ß2-agonist (SABA) use: a post hoc analysis of the EMAX trial Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020 Late Breaking Abstract - Extrafine triple therapy reduces exacerbations in GOLD B COPD patients: post-hoc analysis of TRILOGY and TRINITY Source: International Congress 2017 – Update and new perspectives in Airway Diseases Year: 2017 Efficacy of aclidinium/formoterol: pooled post hoc analysis of patients naïve to COPD maintenance therapy Source: International Congress 2017 – COPD management Year: 2017 Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) versus open-label tiotropium (Tio) in COPD patients: Post hoc analysis from SHINE and SPARK studies Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Nintedanib in IPF: post hoc analysis of the Italian FIBRONET observational study Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Late Breaking Abstract - Risk of a severe exacerbation following higher reliever use: post-hoc analysis of SYGMA 1 in mild asthma Source: International Congress 2018 – Variant forms of asthma Year: 2018 Predictors of loss of asthma control in the Phase 2a INCONTRO trial: A post-hoc analysis Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) versus fluticasone/salmeterol (FLU/SAL) in ex-smoker and never smoker patients with inadequately controlled asthma: Post hoc analysis of IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Reduction in asthma exacerbations with indacaterol/glycopyrronium/mometasone high-dose versus medium-dose: a post hoc analysis from the IRIDIUM study Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Late Breaking Abstract - Reduction of COPD exacerbations with extrafine single inhaler triple therapy: post-hoc analysis by exacerbation treatment of the TRIBUTE study Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018 Mortality and exacerbation prediction by GOLD groups ABCD 2011 vs. 2017: analysis of the COPDGene cohort Source: International Congress 2017 – COPD management: new findings from large studies Year: 2017 Efficacy of revefenacin based on GOLD 2017 categories: reanalysis of phase 3 data in patients with COPD Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Validation of the codex index in patients with COPD enrolled in randomized clinical trials: A post-hoc analysis of the trilogy, trinity and tribute studies. Source: Virtual Congress 2020 – New tools for risk stratification of obstructive diseases Year: 2020 Clinical characteristics and outcomes of elderly patients with COPD: TIOSPIR® post-hoc analysis Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 An Italian, observational, multicenter trial to describe the therapeutic approach according to COPD GOLD guidelines during three years of observation: The MISTRAL study Source: International Congress 2014 – Clinical assessment of airway diseases Year: 2014 Impact of turnaround time on outcome with point-of-care testing for respiratory viruses: a post hoc analysis from a randomised controlled trial Source: Eur Respir J, 52 (2) 1800555; 10.1183/13993003.00555-2018 Year: 2018